Micafungin
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candida
Conditions
Candida
Trial Timeline
Aug 1, 2007 โ Oct 1, 2007
NCT ID
NCT00818584About Micafungin
Micafungin is a phase 1 stage product being developed by Astellas Pharma for Candida. The current trial status is completed. This product is registered under clinical trial identifier NCT00818584. Target conditions include Candida.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
8 competing products in Candida
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Efalizumab | Merck | Approved | 85 |
| AMO959 + Enzalutamide + Abiraterone | Novartis | Phase 1/2 | 41 |
| Clotrimazole 1% (Empecid L Cream, BAYB5097) | Bayer | Pre-clinical | 20 |
| Fluconazole + SCY-078 | Scynexis | Phase 2 | 44 |
| Ibrexafungerp + Placebo | Scynexis | Phase 3 | 69 |
| Ibrexafungerp + Placebo | Scynexis | Phase 3 | 69 |
| hLF1-11 + hLF1-11 + Placebo | AM-Pharma | Phase 1/2 | 33 |